MedPiper Technologies vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru Diagnostics-as-a-Service API connecting 10,000+ India labs for telehealth and insurers; YC W20 $3.28M at 91% YoY growth enabling digital health platforms to embed diagnostics without logistics.
About
MedPiper Technologies is a Bengaluru-based Diagnostics-as-a-Service (DaaS) platform — India's first comprehensive diagnostic infrastructure API — enabling insurers, health plans, telehealth providers, and healthcare organizations to embed diagnostic services (lab tests, radiology, home sample collection) into their digital health workflows through a single white-label integration. Founded in 2020 and backed by Y Combinator (W20) with $3.28 million raised, MedPiper generates ₹5.57 crore (approximately $670,000 USD) in annual revenue with 91% year-over-year growth, serving the digital health ecosystem as the infrastructure layer that connects healthcare platforms to India's fragmented diagnostic laboratory network.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.